1000 WINTER ST, SUITE 1200, WALTHAM, MA
Zenas BioPharma Completes $200 Million Convertible Notes Offering
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Zenas BioPharma Approves Amended Short-Term Incentive Plan
Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
Announce License Agreement Granting Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
FY 2025
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Free Writing Prospectus
Prospectus filed pursuant to Rule 424(b)(7)